Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy and have been exposed to an anti-cluster of differentiation 38 (CD38) antibody, lenalidomide, a proteasome inhibitor (PI) and a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy.

Trial Details

NCT ID
NCT07825064
Phase
PHASE2
Sponsor
Hoffmann-La Roche
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Cevostamab
  • Pomalidomide
  • Dexamethasone
  • Tocilizumab
Locations (sample)
  • Nuremberg, Bavaria, Germany|49.45421,11.07752
  • Greifswald, Germany|54.08905,13.40244
  • Heidelberg, Germany|49.40768,8.69079
  • Jena, Germany|50.92878,11.5899
  • Kiel, Germany|54.32133,10.13489

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to the start of administration of study t…
  • Received one to four lines of prior therapy, including prior B-cell maturation antigen (BCMA)-targeting Chimeric Antigen Receptors (CAR) T-cell the…
  • Multiple Myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
  • Is triple-class exposed, i.e. received anti- cluster of differentiation 38 (CD38) therapy, a proteasome inhibitor (PI) and lenalidomide in any prio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →